Net Sales are expected to increase by 7.3 percent Y-o-Y (down 1 percent Q-o-Q) to Rs. 3,969.1 crore, according to Kotak.
Kotak has come out with its fourth quarter (January-March’ 19) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Cipla to report net profit at Rs. 295.8 crore up 93.2% year-on-year (down 11% quarter-on-quarter).
Net Sales are expected to increase by 7.3 percent Y-o-Y (down 1 percent Q-o-Q) to Rs. 3,969.1 crore, according to Kotak.
Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 9.1 percent Y-o-Y (down 14.1 percent Q-o-Q) to Rs. 607.5 crore.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Read More
